Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Insulin Manufacturer For Civica

Civica Enlists Swiss Ypsomed To Make Injector Pens

Executive Summary

Ypsomed AG will manufacture insulin dosing injector pens for non-profit Civica. Civica has also paired up with AmerisourceBergen for generics supply chain support across the US.

You may also be interested in...

US Aspart Filing Kicks Off Amphastar’s Insulin Ambitions

Amphastar says a “milestone” submission of a US filing for insulin aspart underlines its ambitions in the diabetes segment. But could the firm get the first US biosimilar approval?

Non-Profit Outpatient Player CivicaScript Brings Packaging Specialist Aboard

As it continues plans to roll out low-cost insulin biosimilar products, CivicaScript has augmented its existing product offering via a collaboration with specialty pharmacy SortPak.

California Snaps Up Civica For Biosimilar Insulin Initiative

Civica is set to provide biosimilar insulins to the state of California through its CalRx program, following approval from the US Food and Drug Administration.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts